Single nucleotide polymorphisms (SNPs) are one of the fastest-growing areas of genomic research. This field has advanced much more rapidly than ever anticipated, and extensive progress has been made in mapping SNPs both in the public (The SNP Consortium) and private arenas. Also, throughput capacity is rapidly increasing in this field. Now, the focus is shifting to validating SNPs and to using SNP data to identify novel disease targets.
This report provides in-depth coverage of more than 30 companies that are offering advanced technologies for SNP discovery and detection. These companies include Affymetrix (Perlegen), Amersham Pharmacia Biotech, Applied Biosystems, GlaxoSmithKline, Illumina, Luminex, Lynx Therapeutics, Molecular Devices, Nanogen, Third Wave Technologies, Orchid BioSciences, Qiagen, Sequenom, and Variagenics.
This report also discusses important busines and technical trends. Notably, demand for genotyping tools is set to increase as a growing number of companies begin integrating SNP data collection into drug and diagnostic. Commentaries or direct quotes are included from over 20 leading experts in the field.
View Cart
